Abstract Library

#4466 Molecular characterisation of extrapulmonary mixed adeno-neuroendocrine neoplasms (MiNENs): The NIRVANA sub study

Introduction: Extrapulmonary (EP) mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) are rare cancers with a dismal prognosis. The gene mutation profiles are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: MiNEN, NGS, ESCAT, chemotherapy,

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#4046 A single institution experience of clinic-molecular characterisation and correlation with treatment outcomes in patients with advanced extrapulmonary high grade neuroendocrine carcinomas: The NIRVANA study

Introduction: The gene mutation profiles of extra-pulmonary (EP) neuroendocrine carcinomas (NECs) and mixed neuroendocrine / non-neuroendocrine carcinomas (MiNENs) are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: NEC, MiNEN, NGS, KRAS, TP53, MSI, extra-pulmonary,

#3969 A case report of a high-grade pancreatic NET patient with high tumor mutation burden who benefited from chemotherapy combined with immunotherapy

Introduction: For patients with well-differentiated G3 NET, the efficacy of immune checkpoint inhibitors (ICIs) is currently not clear. The expression level of PD-L1 in tumor tissue, high microsatellite instability (MSI-H), and high tumor mutational burden (TMB-H) are considered indicators for selecting potential beneficiaries of immunotherapy.

Conference:

Presenting Author:

Authors: Jia X, Liang Y, Chen J,

Keywords: g3 pancreatic net, captem, tmb-h, icis,

#3633 Tumor mutation burden in gastroenteropancreatic neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are rare tumors with limited treatment options. Microsatellite instability (MSI) and tumor mutation burden (TMB) are novel biomarkers in various tumor types. However, few studies have been performed for these novel biomarkers in gastroenteropancreatic (GEP)- NENs.

Conference:

Presenting Author: Sun Young J

Authors: Sun Young J, Seung Tae K, Young Suk P, Jeeyun L,

Keywords: tumor mutation burden, neuroendocrine tumor, neuroendocrine carcinoma, gastroenteropancreatic neuroendocrine neoplasm,